Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial.
Naimi RM, Hvistendahl M, Nerup N, Ambrus R, Achiam MP, Svendsen LB, Grønbæk H, Møller HJ, Vilstrup H, Steensberg A, Jeppesen PB. Naimi RM, et al. Among authors: jeppesen pb. EBioMedicine. 2019 Aug;46:444-451. doi: 10.1016/j.ebiom.2019.07.016. Epub 2019 Jul 17. EBioMedicine. 2019. PMID: 31326433 Free PMC article. Clinical Trial.
Glucagon like peptide-2 and neoplasia; a systematic review.
Ring LL, Nerup N, Jeppesen PB, Svendsen LB, Achiam MP. Ring LL, et al. Among authors: jeppesen pb. Expert Rev Gastroenterol Hepatol. 2018 Mar;12(3):257-264. doi: 10.1080/17474124.2018.1417032. Epub 2017 Dec 19. Expert Rev Gastroenterol Hepatol. 2018. PMID: 29231791 Review.
Effect of Glepaglutide, a Long-Acting Glucagon-Like Peptide-2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial.
Hvistendahl MK, Naimi RM, Enevoldsen LH, Madsen JL, Fuglsang S, Jeppesen PB. Hvistendahl MK, et al. Among authors: jeppesen pb. JPEN J Parenter Enteral Nutr. 2020 Nov;44(8):1535-1544. doi: 10.1002/jpen.1767. Epub 2020 Feb 5. JPEN J Parenter Enteral Nutr. 2020. PMID: 32022286 Clinical Trial.
Effect of Liraglutide Treatment on Jejunostomy Output in Patients With Short Bowel Syndrome: An Open-Label Pilot Study.
Hvistendahl M, Brandt CF, Tribler S, Naimi RM, Hartmann B, Holst JJ, Rehfeld JF, Hornum M, Andersen JR, Henriksen BM, Brøbech Mortensen P, Jeppesen PB. Hvistendahl M, et al. Among authors: jeppesen pb. JPEN J Parenter Enteral Nutr. 2018 Jan;42(1):112-121. doi: 10.1177/0148607116672265. Epub 2017 Dec 11. JPEN J Parenter Enteral Nutr. 2018. PMID: 27875281
A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients.
Naimi RM, Madsen KB, Askov-Hansen C, Brandt CF, Hartmann B, Holst JJ, Mortensen PB, Jeppesen PB. Naimi RM, et al. Among authors: jeppesen pb. Regul Pept. 2013 Jun 10;184:47-53. doi: 10.1016/j.regpep.2013.03.023. Epub 2013 Mar 15. Regul Pept. 2013. PMID: 23501043
Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study.
Madsen KB, Askov-Hansen C, Naimi RM, Brandt CF, Hartmann B, Holst JJ, Mortensen PB, Jeppesen PB. Madsen KB, et al. Among authors: jeppesen pb. Regul Pept. 2013 Jun 10;184:30-9. doi: 10.1016/j.regpep.2013.03.025. Epub 2013 Mar 16. Regul Pept. 2013. PMID: 23511332 Clinical Trial.
252 results